Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.

[1]  A. Antonelli,et al.  Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. , 2015, Autoimmunity reviews.

[2]  Kamal K Solanki,et al.  Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? , 2015, Rheumatology.

[3]  G. de Luca,et al.  Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. , 2015, Seminars in arthritis and rheumatism.

[4]  D. Huscher,et al.  Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group , 2014, Annals of the rheumatic diseases.

[5]  D. Elewaut,et al.  Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement , 2013, The Journal of Rheumatology.

[6]  Y. Allanore,et al.  Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. , 2012, Rheumatology.

[7]  G. Ferraccioli,et al.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial , 2010, Arthritis research & therapy.

[8]  C. Kalogeropoulou,et al.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study , 2009, Rheumatology.

[9]  P. Merkel,et al.  B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. , 2009, Arthritis and rheumatism.

[10]  L. Mouthon,et al.  Interstitial Lung Disease Associated with Systemic Sclerosis , 2007, Annals of the New York Academy of Sciences.

[11]  G. Hawker,et al.  Classification criteria for systemic sclerosis subsets. , 2007, The Journal of rheumatology.

[12]  E. Matteson,et al.  B cell infiltration in systemic sclerosis-associated interstitial lung disease. , 2007, Arthritis and rheumatism.

[13]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[14]  R. Fleischmajer,et al.  Ultrastructure of cutaneous cellular infiltrates in scleroderma. , 1977, Archives of dermatology.

[15]  R. Panush.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis , 2011 .

[16]  B. Berman.  Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study , 2011 .

[17]  A. Gabrielli,et al.  Mechanisms of Disease Scleroderma , 2009 .

[18]  B. Thiers.  Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2007 .

[19]  Y. Yamashita,et al.  Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. , 2006, Radiology.